Zepbound Vial Prices Dropped by Eli Lilly

Eli Lilly has reduced the cash prices of its single-dose Zepbound weight-loss drug vials on its LillyDirect platform, lowering monthly costs by up to $50.

sarah

Dec 1, 2025 - 19:15

Zepbound Vial Prices Dropped by Eli Lilly

Eli Lilly announced Monday that it is lowering the cash prices of single-dose vials of its blockbuster weight loss drug, Zepabound, on its direct-to-consumer platform, LillyDirect. This is in line with the company and the Trump administration's efforts to make the drug more accessible.

The announcement comes just weeks after its main competitor, Novo Nordisk, offered additional discounts on the cash prices of its obesity and diabetes drugs.

Starting Monday, cash-paying patients with a valid prescription can get their initial dose of Zepabound vials on LillyDirect for as low as $299 per month, down from $349 per month previously. They can get the next dose – 5 mg – for $399 per month, and all remaining doses for $449 per month, down from $499 per month for these sizes.

Zepbound's list price is approximately $1,086 per month. U.S. That price and poor insurance coverage for weight-loss drugs in the U.S. have been major barriers to access for some patients.

Eli Lilly's announcement comes just weeks after President Donald Trump struck a deal with Eli Lilly and Novo Nordisk to make it easier for Americans to access and afford their GLP-1 medications. These agreements will reduce government-paid drug prices, open Medicare coverage of obesity medications for some patients for the first time, and make discounted medications available on the government's new direct-to-consumer website, TrumpRx, launching in January.

But Eli Lilly's deal with Trump is about reducing the price of a different form of Zepbound—a multi-dose pen—once it receives approval from the Food and Drug Administration.

This means that more patients could get discounted treatment more quickly than Eli Lilly's Monday announcement about price reductions on existing single-dose vials.

Ilya Yufa, president of Lilly USA and Global Customer Capabilities, said in a statement, “We will continue to provide more options – expanding delivery device options and creating new avenues for access – so more people can get the medicines they need.”

With single-dose vials, patients use a syringe and needle to draw up the medication and inject themselves. Eli Lilly first introduced that form of Zepabound in August 2024.

It is unclear how many patients are currently taking single-dose vials of Zepabound. However, Eli Lilly has previously stated that direct-to-consumer sales now account for more than a third of new Zepabound prescriptions.

Earlier this month, Novo Nordisk reduced the price of its obesity drug Wegovy and diabetes treatment Ozempic from $499 per month to $349 per month for existing cash-paying patients. This does not include the highest dose of Ozempic.

The company has also launched a temporary introductory offer, allowing new cash-paying patients to receive the two lowest doses of Wegovy and Ozempic for $199 per month for the first two months of treatment.